Inflammatory bowel disease (IBD) is a chronic relapsing disorder modulated by numerous\nfactors. Recent failures of drugs targeting single factors suggest that multitargeting drugs could be\nuseful for the treatment of IBD. Natural medicines may be an alternative option for the treatment of\nIBD, owing to the complex nature of the disease. However, most natural medicines have poor in vitro\nand in vivo translational potential because of inadequate pharmacokinetic study. KM1608, a mixture\nof the medicinal plants Aucklandia lappa, Terminalia chebula, and Zingiber officinale, was examined for\nits anti-colitis effects and biodistribution using bioimaging. Dehydrocostus lactone, as a marker\ncompound, was analyzed to assess the biodistribution of KM1608. KM1608 significantly attenuated\nthe disease activity of dextran sodium sulfate-induced colitis in mice and suppressed inflammatory\nmediators such as myeloperoxidase, proinflammatory cytokines..............................
Loading....